Generally manageable safety profile with largely mild-to-moderate adverse reactions1,2

Data described here are reflective of the 476 patients treated with LORVIQUA in the Phase 1/2 study of previously treated patients and the Phase 3 CROWN study of previously untreated patients.1,2

The most common adverse reactions are reported below.

ARs (any grade) occurring in ≥20% of patients treated with LORVIQUA (N=476)1
Scroll left to view table
Adverse reaction All grades Grades 3 and 4
Hypercholesterolaemiaa 81.1% 18.3%
Hypertriglyceridaemiab 67.2% 19.3%
Oedemac 55.7% 2.7%
Peripheral neuropathyd 43.7% 2.7%
Weight increased 30.9% 10.1%
Cognitive effectse 27.7% 2.9%
Fatiguef 27.3% 1.3%
Arthralgia 23.5% 0.8%
Diarrhoea 22.9% 1.5%
Mood effectsg 21.0% 1.5%
  • In the CROWN study, permanent discontinuations and dose reductions associated with adverse reactions occurred in 7.0% and 21.0% of patients with LORVIQUA and 9.0% and 15.0% with crizotinib, respectively3,h
  • 35.0% of patients receiving LORVIQUA in the CROWN study reported CNS adverse events, but by the time of analysis 56.0% had resolved and most required no intervention (33.0% resolved without intervention, 17.0% with dose modification)4,h, 
  • Adverse reactions can be effectively managed with dose modifications and/or standard supportive medical therapy, without affecting the efficacy of LORVIQUA4,5 

Learn more about therapy management

ReferencesRefer to the LORVIQUA Summary of Product Characteristics for the most up-to-date safety profile.AR=adverse reaction; NSCLC=non-small cell lung cancer; SOC=system organ class.aHypercholesterolaemia (including blood cholesterol increased, hypercholesterolaemia).bHypertriglyceridaemia (including blood triglycerides increased, hypertriglyceridaemia).cOedema (including generalised oedema, oedema, oedema peripheral, peripheral swelling, swelling).dPeripheral neuropathy (including burning sensation, dysaesthesia, formication, gait disturbance, hypoaesthesia, motor dysfunction, muscular weakness, neuralgia, neuropathy peripheral, neurotoxicity, paraesthesia, peripheral motor neuropathy, peripheral sensory neuropathy, peroneal nerve palsy, sensory disturbance).eCognitive effects (including events from SOC nervous system disorders: amnesia, cognitive disorder, dementia, disturbance in attention, memory impairment, mental impairment; and also including events from SOC psychiatric disorders: attention deficit/hyperactivity disorder, confusional state, delirium, disorientation, reading disorder). Within these effects, terms from SOC nervous system disorders were more frequently reported than terms from SOC psychiatric disorder.fFatigue (including asthenia, fatigue).gMood effects (including affective disorder, affect lability, aggression, agitation, anger, anxiety, bipolar I disorder, depressed mood, depression, depressive symptom, euphoric mood, irritability, mania, mood altered, mood swings, panic attack, personality change, stress).hBased on data from 18-month median follow-up of 149 patients who received LORVIQUA 100 mg once daily in the Phase 3 CROWN trial.3ReferencesReferences:Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-­cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654-1667.Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383{21):2018-2029.Solomon BJ, Bauer TM, Ou SHI, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the Phase III CROWN study. J Clin Oncol. Published online May 23, 2022. doi: 10.1200/JCO.21.02278.Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019;24(8):1103-1110. Safety
Therapy management
 See the strategiesLoading
LORVIQUA efficacy
 Discover the data Loading
PP-LOR-IRL-0073 February 2024 Legal Category S1A Further information available on request
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024